A Racial/Ethnic Performance Disparity on the Facial Recognition Test

The Facial Recognition Test is a widely used psychometric instrument for assessing visuoperceptual functioning. Only two prior studies have examined the effects of race/ethnicity on this test. Given that the United States has become more culturally diverse since the creation of the test, it is important to re-visit the effects of this demographic variable on performance. Participants were 75 males and 75 females between the ages of 18 and 43 years (M = 21.91, SD = 5.33). Racial/ethnic categories utilized by the U.S. Census Bureau were equally represented. No gender differences were observed. The race/ethnicity main effect was significant. The gender x race/ethnicity interaction was not significant. The data revealed a clear racial/ethnic performance disparity on the Facial Recognition Test

Content Validity of the Geriatric Depression Scale in Inpatient Health Care Settings

The content validity of the Geriatric Depression Scale (GDS) for use in inpatient health care settings was evaluated. Clinical experience has shown that one or more questions may not be appropriate in such settings. These questions ask about behaviors or feelings with which the examinee may not be able to identify with because they have been in an inpatient setting during the past week. Twenty-five Subject Matter Experts (SMEs) evaluated the GDS-30 as to whether each item appropriately assesses the construct of depression for inpatients in a medical care setting. SMEs were identified by an online search of the Florida Division of Medical Quality Assurance database; inclusion criteria are presented. Nineteen SMEs held a Ph.D. and six held a Psy.D. Years of post-licensure practice experience ranged from 10 to 48 years with a mean of 23.12 years (SD = 10.07). Using the Content Validity Ratio, four questions emerged as inappropriate (statistically significant at, or below, an alpha level of .025). The lack of content validity of these questions necessitates their omission when psychometrically assessing depression in elderly inpatients. Recommended revised cutoff values are presented. Utilizing the recommended modification to the GDS presented here should reduce false positives when psychometrically assessing depression in elderly inpatients

A systematic review of non-antibiotic measures for the prevention of urinary tract infections in pregnancy

Background: Urinary tract infections (UTIs) are common in pregnancy and account for the highest proportion of primary care antibiotic prescriptions issued to pregnant women in the UK. It is well known that antibiotic use is associated with increased antimicrobial resistance and therefore measures to minimise antibiotic use for UTI prevention have been studied. The efficacy and safety of these measures in pregnancy have not been addressed and therefore the aim of this study was to systematically review the literature to identify and evaluate potential measures to prevent UTIs in pregnant women. Methods: Ten databases (EMBASE, AMED, BNI, CINAHL, Medline, PubMed, PsycINFO, Cochrane Trials, Scopus and Science Direct) were systematically searched in July 2017 for studies reporting non-antibiotic measures to prevent UTIs in pregnancy. The terms (“urinary tract infection”or UTI or bacteriuria or cystitis) AND (prevention) AND (pregnan*) were used. The quality of the publications was appraised using the Critical Appraisal Skills Programme (CASP) checklists for cohort study, case-control study and randomised controlled trial. The results were synthesised using a textual narrative approach. Results: Search results yielded 3276 publications and after reviewing titles and removing duplicates, 57 full text articles were assessed for eligibility and eight were included in the review. Five different approaches (hygiene measures, cranberry juice, immunisation, ascorbic acid and Canephron® N) have been identified, all of which are reported to be safe in pregnancy. Conclusion: The quality of the evidence varied considerably and only hygiene measures were supported by evidence to be recommended in practice. Future work needs to concentrate on strengthening the evidence base through improved design and reporting of studies with a focus on immunisation, ascorbic acid and Canephron® N

Signal Detection in EUROmediCAT: Identification and Evaluation of Medication–Congenital Anomaly Associations and Use of VigiBase as a Complementary Source of Reference

Introduction Knowledge on the safety of medication use during pregnancy is often sparse. Pregnant women are generally excluded from clinical trials, and there is a dependence on post-marketing surveillance to identify teratogenic medications. Aims This study aimed to identify signals of potentially teratogenic medications using EUROmediCAT registry data on medication exposure in pregnancies with a congenital anomaly, and to investigate the use of VigiBase reports of adverse events of medications in the evaluation of these signals. Methods Signals of medication–congenital anomaly associations were identified in EUROmediCAT (21,636 congenital anomaly cases with 32,619 medication exposures), then investigated in a subset of VigiBase (45,749 cases and 165,121 exposures), by reviewing statistical reporting patterns and VigiBase case reports. Evidence from the literature and quantitative and qualitative aspects of both datasets were considered before recommending signals as warranting further independent investigation. Results EUROmediCAT analysis identified 49 signals of medication–congenital anomaly associations. Incorporating investigation in VigiBase and the literature, these were categorised as follows: four non-specific medications; 11 likely due to maternal disease; 11 well-established teratogens; two reviewed in previous EUROmediCAT studies with limited additional evidence; and 13 with insufficient basis for recommending follow-up. Independent investigations are recommended for eight signals: pregnen (4) derivatives with limb reduction; nitrofuran derivatives with cleft palate and patent ductus arteriosus; salicylic acid and derivatives with atresia or stenosis of other parts of the small intestine and tetralogy of Fallot; carbamazepine with atrioventricular septal defect and severe congenital heart defect; and selective beta-2-adrenoreceptor agonists with posterior urethral valve and/or prune belly. Conclusion EUROmediCAT data should continue to be used for signal detection, accompanied by information from VigiBase and review of the existing literature to prioritise signals for further independent evaluation